
    
      Prospective randomised controlled study. Patients with Crohn's Disease who have symptomatic
      inflammatory intestinal strictures will be randomised to receive standard drug therapy
      (Anti-TNF monotherapy at standard dose) or intensive drug therapy (Intense Anti-TNF dose
      induction and escalation for continued inflammation in combination with thiopurine) for 12
      months.
    
  